Luigi Gugliotta Selected Research

anagrelide (Agrylin)

1/2018	Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.
6/2015	Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study.
4/2014	Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
12/2011	Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Luigi Gugliotta Research Topics

Disease

7	Essential Thrombocythemia 01/2018 - 02/2004
3	Leukemia 01/2018 - 09/2003
3	Hemorrhage 01/2018 - 01/2008
3	Infections 12/2008 - 09/2004
2	Neoplasms (Cancer) 01/2018 - 01/2016
2	Thrombocytosis (Thrombocythemia) 01/2016 - 12/2011
2	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 04/2010 - 02/2007
2	Thrombosis (Thrombus) 01/2008 - 08/2007
2	Polycythemia Vera 01/2008 - 04/2005
2	Hematologic Neoplasms (Hematological Malignancy) 09/2004 - 09/2003
1	Primary Myelofibrosis (Myelosclerosis) 01/2018
1	Pruritus (Itching) 12/2015
1	Myocardial Infarction 01/2013
1	Heart Failure 01/2013
1	acquired Thrombotic thrombocytopenic purpura 06/2010
1	Thrombotic Thrombocytopenic Purpura 06/2010
1	Mycoses (Diseases, Fungus) 11/2008
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 03/2008
1	Venous Thromboembolism 03/2008
1	Acute Coronary Syndrome 03/2008
1	Pathologic Complete Response 10/2005
1	Thrombocytopenia (Thrombopenia) 09/2004
1	Neutropenia 09/2004
1	Myeloid Sarcoma (Chloroma) 09/2004
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 09/2004
1	Lymphoma (Lymphomas) 09/2003

Drug/Important Bio-Agent (IBA)

4	anagrelide (Agrylin)FDA LinkGeneric 01/2018 - 12/2011
2	Dexamethasone (Maxidex)FDA LinkGeneric 04/2010 - 02/2007
2	Inosine Triphosphate (ITP)IBA 04/2010 - 02/2007
2	Etoposide (VP 16)FDA LinkGeneric 11/2008 - 10/2005
1	Biological ProductsIBA 01/2016
1	Hemostatics (Antihemorrhagics)IBA 01/2016
1	Interferon-alpha (Interferon Alfa)IBA 12/2015
1	pro-brain natriuretic peptide (1-76)IBA 06/2015
1	Troponin IIBA 06/2015
1	diethylstilbestrol monophosphate (PDES)IBA 01/2013
1	Methylprednisolone FDA LinkGeneric 06/2010
1	thiamine triphosphorate (TTP)IBA 06/2010
1	Rituximab (Mabthera)FDA Link 04/2010
1	galactomannanIBA 12/2008
1	fludarabineIBA 11/2008
1	CytosineIBA 11/2008
1	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 11/2008
1	AnticoagulantsIBA 03/2008
1	Vitamin K FDA Link 03/2008
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 03/2008
1	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2007
1	Mitoxantrone (Novantrone)FDA LinkGeneric 10/2005
1	Cytarabine (Cytosar-U)FDA LinkGeneric 10/2005
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 04/2005
1	OligonucleotidesIBA 11/2004
1	Gemtuzumab (Mylotarg)FDA Link 09/2004
1	CalicheamicinsIBA 09/2004
1	BilirubinIBA 09/2004
1	Transaminases (Aminotransferases)IBA 09/2004
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 09/2003

Therapy/Procedure

5	Therapeutics 01/2018 - 02/2004
4	Drug Therapy (Chemotherapy) 11/2008 - 09/2003
1	Plasma Exchange 06/2010
1	Induction Chemotherapy 11/2008
1	Operative Surgical Procedures 01/2008
1	Stem Cell Transplantation 10/2005
1	Autologous Transplantation 09/2003
1	Transplantation 09/2003